Barclays raised the firm’s price target on Arvinas (ARVN) to $20 from $18 and keeps an Overweight rating on the shares post the Q1 report. The firm says the company’s Veppanu commercial agreement announcement is a positive. It continues to like Arvinas’ early pipeline.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Faces Key Commercialization Risk as VEPPANU’s Success Hinges on Third‑Party Partner with Pfizer
- Arvinas Earnings Call: PROTAC Breakthrough and New Risks
- H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
- Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
- Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer